Charles River Laboratories Intl. Inc vs Rush Street Interactive Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Rush Street Interactive Inc trades at $18.9 (market cap $2.35B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 6.1× Rush Street Interactive Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Rush Street Interactive Inc for 13 Days on average.
| CRL | RSI | |
|---|---|---|
Market Cap | $14.23B | $2.35B |
Volume | 1,176,885 | 2,219,374 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $34.52 |
52-Week Low | $149.93 | $15.89 |
Typical Hold Time | 33 Days | 13 Days |
Enterprise Value | $17.06B | $2.01B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Rush Street Interactive (RSI) trades at $20.32, up 0.4% on the day, with a bearish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates, and revenue growth from $1.13B in 2025 to $1.4B in 2026. Analyst consensus is bullish with a $34.88 price target, though net income margin compression from 2.93% to 2.33% highlights profitability challenges.
RSI presents a mixed outlook: robust revenue growth and solid analyst support contrast with thin margins and bearish technicals. The stock offers upside to consensus targets but faces execution risks in a competitive online betting market. Investors should weigh growth potential against margin pressures and market sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →